Overall, these data suggest estradiol-induced resistance is a shared characteristic across all three classes of PI3K pathway inhibitors tested, but there is marked heterogeneity in the inhibitory effect of estradiol across ER-positive breast cancer cell lines. The gene discussed is PIK3CA; the disease is breast carcinoma.